Top

Published in:

01-05-2013 | Original Article

Potassium Depolarization and Raised Calcium Induces α-Synuclein Aggregates

Authors: Jordan Follett, Bonnie Darlow, Mathew B. Wong, Jacob Goodwin, Dean L. Pountney

Published in: Neurotoxicity Research | Issue 4/2013

Abstract

α-Synuclein is the key aggregating protein in Parkinson’s disease (PD), which is characterized by cytoplasmic protein inclusion bodies, termed Lewy bodies, thought to increase longevity of the host neuron by sequestering toxic soluble α-synuclein oligomers. Previous post-mortem studies have shown relative sparing of neurons in PD that are positive for the Ca²⁺ buffering protein, calbindin, and recent cell culture and in vitro studies have shown that α-synuclein aggregation can be induced by Ca²⁺. We hypothesized that depolarization with potassium resulting in raised Ca²⁺ in a PD cell culture model will lead to the formation of α-synuclein protein aggregates and that the intracellular Ca²⁺ buffer, BAPTA-AM, may suppress their formation. Live cell fluorescence microscopy was performed to monitor changes in intracellular free calcium in HEK293T, SH-SY5Y neuroblastoma or stably transfected HEK293T/α-synuclein cells. Raised intracellular free Ca²⁺ was consistently observed in cells treated with KCl, but not controls. Immunohistochemistry analysis on cells 48–72 h after K⁺ treatment revealed two subsets of cells with either large (>2 μm), perinuclear α-synuclein aggregates or multiple smaller (<2 μm), cytoplasmic accumulations. Cells pre-treated with varying concentrations of trimethadione (TMO), a calcium channel blocker, showed suppression of the Ca²⁺ transient following KCl treatment and no α-synuclein aggregates at TMO concentrations >5 μM. Quantitative analysis revealed a significant increase in the number of cells bearing α-synuclein cytoplasmic inclusions in both HEK293T/α-synuclein and SHSY-5Y cells when transient intracellular raised Ca²⁺ was induced (p = 0.001). BAPTA-AM pre-loading significantly suppressed α-synuclein aggregates (p = 0.001) and the intracellular free Ca²⁺ transient. This study indicates that raised intracellular Ca²⁺ mediated by K⁺ depolarization can lead to α-synuclein aggregation.

Berjukow S, Döring F, Froschmayr M, Grabner M, Glossmann H, Hering S (1996) Endogenous calcium channels in human embryonic kidney (HEK293) cells. Br J Pharmacol 118(3):748–754PubMedCrossRef

Bezprozvanny I (2009) Calcium signaling and neurodegenerative diseases. Trends Mol Med 15:89–100PubMedCrossRef

Bezprozvanny I, Tsien RW (1995) Voltage-dependent blockade of diverse types of voltage-gated Ca²⁺ channels expressed in Xenopus oocytes by the Ca²⁺ channel antagonist mibefradil (Ro 40-5967). Mol Pharm 48:540–549

Breydo L, Wu JW, Uversky VN (2012) Α-synuclein misfolding and Parkinson’s disease. Biochim Biophys Acta 1822:261–285PubMedCrossRef

Bruseell R Jr, Eliezer D (2003) A structural and functional role for 11-mer repeats in alpha synuclein and other exchangeable lipid binding proteins. J Mol Biol 329:763–778CrossRef

Chemin J, Monteil A, Perez-Reyes E, Nargeot J, Lory P (2001) Direct inhibition of T-type calcium channels by the endogenous cannabinoid anandamide. EMBO J 70:7033–7040CrossRef

Chin LS, Olzmann JA, Li L (2010) Parkin-mediated ubiquitin signalling in aggresome formation and autophagy. Biochem Soc Trans 38:144–149PubMedCrossRef

Conway K, Lee S, Rochet J, Ding T, Williamson R, Lansbury P Jr (2000) Acceleration of oligomerization, not fibrilization, is a shared property of both α synuclein mutations linked to early-onset Parkinson’s disease: implications for pathogenesis and therapy. Proc Natl Acad Sci USA 99:571–576CrossRef

Cookson MR (2009) alpha-Synuclein and neuronal cell death. Mol Neurodegener 4:9PubMedCrossRef

Corrales A, Montoya GJV, Sutachan JJ, Cornillez-Ty G, Garavito-Aguilar Z, Xu F, Blanck TJJ, Recio-Pinto E (2005) Transient increases in extracellular K+ produce two pharmacological distinct cytosolic Ca²⁺ transients. Brain Res 1031:174–184PubMedCrossRef

Desai A et al (2006) Human neuroblastoma (SH-SY5Y) cell culture and differentiation in 3-D collagen hydrogels for cell-based biosensing. Biosens Bioelectron 21:1483–1492PubMedCrossRef

Dohm CP, Kermer P, Bahr M (2008) Aggregopathy in neurodegenerative diseases: mechanism and therapeutic implication. Neurodegener Dis 5:321–338PubMedCrossRef

Dufty BM, Warner LR, Hou ST, Jiang SX, Gomez-Isla T, Leenhouts KM, Oxford JT, Feany MB, Masliah E, Rohn TT (2007) Calpain-cleavage of alpha-synuclein: connecting proteolytic processing to disease-linked aggregation. Am J Pathol 170(5):1725–1738PubMedCrossRef

Ertel SI, Ertel EA, Clozel JP (1997) T-type Ca²⁺ channels and pharmacological blockade: potential pathophysiological relevance. Cardiovasc Drugs Ther 11:723–739PubMedCrossRef

Feany MB, Bender WW (2000) A Drosophila model of Parkinson’s disease. Nature 404:394–398PubMedCrossRef

Fredenburg RA, Rospigliosi C, Meray RK, Kessler JC, Lashuel HA, Eliezer D, Lansbury PT (2007) The impact of the E46K mutant on the properties of alpha-synuclein in its monomeric and oligomeric states. Biochemistry 46:7107–7118PubMedCrossRef

Freedman SB et al (1984) Identification and characterization of voltage-sensitive calcium channels in neuronal clonal cell lines. J Neurosci 4(6):1453–1467PubMed

Garcia-mata R, Bebok Z, Sorscher EJ, Sztul ES (1999) Characterization and dynamics of aggresome formation by a cytosolic GFP-chimera. J Cell Biol 146:1239–1254PubMedCrossRef

Goodwin J, Nath S, Engelborghs Y, Pountney DL (2012) Raised calcium and oxidative stress cooperatively promote alpha-synuclein aggregate formation. Neurochem Int. http://dx.doi.org/10.1016/j.neuint.2012.11.004

Heady TN, Gomora JC, Macdonald TL, Perez-Reyes E (2001) Molecular pharmacology of t-type calcium (II) channels. Jpn J Pharmacol 85:339–350PubMedCrossRef

Hettiarachchi NT, Parker A, Dallas ML, Pennington K, Hung CC, Pearson HA, Boyle JP, Robinson P, Peers C (2009) alpha-Synuclein modulation of Ca²⁺ signaling in human neuroblastoma (SH-SY5Y) cells. J Neurochem 111:1192–1201PubMedCrossRef

Huguenard JR (1996) Low-threshold calcium currents in central nervous system neurons. Annu Rev Physiol 58:329–348PubMedCrossRef

Jellinger KA (2009) Formation and development of Lewy pathology: a critical update. J Neurol 256(Suppl 3):270–279PubMedCrossRef

Johnston JA, Ward CL, Kopito RR (1998) Aggresomes: a cellular response to misfolded proteins. J Cell Biol 14:1883–1898CrossRef

Kragh CL, Lund LB, Febbraro F, Hansen HD, Gai WP, El-Agnaf O, Richter-Landsberg C, Jensen PH (2009) {alpha}-Synuclein aggregation and Ser-129 phosphorylation-dependent cell death in oligodendroglial cells. J Biol Chem 284:10211–10222PubMedCrossRef

Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, Przuntek H, Epplen JT, Schols L, Riess O (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson’s disease. Nat Genet 18:106–108PubMedCrossRef

Larsen KE et al (2006) α-Synuclein overexpression in PC12 and chromaffin cells impairs catecholamine release by interfering with a late step in exocytosis. J Neurosci 26:11915–11922PubMedCrossRef

Liu XD, Ko S, Xu Y, Fattah EA, Xiang Q, Jagannath C, Ishii T, Komatsu M, Eissa NT (2012) Transient aggregation of ubiquitinated proteins is a cytosolic unfolded protein response to inflammation and endoplasmic reticulum stress. J Biol Chem 287:19687–19698PubMedCrossRef

Lowe R, Pountney DL et al (2004) Calcium (II) selectively induces α-synuclein annular oligomers via interaction with C-terminal domain. Protein Sci 13(12):3245–3252PubMedCrossRef

Marques O, Outeiro TF (2012) Alpha-synuclein: from secretion to dysfunction and death. Cell Death Dis 3:e350. doi: 10.1038/cddis.2012.94

Mattson MP (2007) Calcium and neurodegeneration. Aging Cell 6:337–350PubMedCrossRef

McLean PJ, Kawamata H, Hyman BT (2001) α-Synuclein enhanced green fluorescent protein fusion proteins form proteasome sensitive inclusions in Primary neurons. Neuroscience 104:901–912PubMedCrossRef

Mosharov EV, Larsen KE, Kanter E, Phillips KA, Wilson K, Schmitz Y, Krantz DE, Kobayashi K, Edwards RH, Sulzer D (2009) Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons. Neuron 62:218–229PubMedCrossRef

Murphy DD, Rueter SM, Trojanowski JQ, Lee VM (2000) Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J Neurosci 20:3214–3220PubMed

Nath S, Goodwin J, Engelborghs Y, Pountney DL (2011) Raised calcium promotes α-synuclein aggregate formation. Mol Cell Neurosci 46:516–526PubMedCrossRef

Nemani VM, Lu W, Berge V, Nakamura K, Onoa B, Lee MK, Chaudhry FA, Nicoll RA, Edwards RH (2010) Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron 65:66–79PubMedCrossRef

Nielsen MS, Vorum H, Lindersson E, Jensen PH (2001) Ca2+ binding to alpha-synuclein regulates ligand binding and oligomerization. J Biol Chem 276:22680–22684PubMedCrossRef

Nikoletopoulou V, Tavernarakis N (2012) Calcium homeostasis in aging neurons. Front Genet 3:200PubMedCrossRef

Park SM, Jung HY, Kim TD, Kim J (2002) Distinct roles of the N-terminal-binding domain and the C-terminal solubilising domain of alpha-synclein, a molecular chaperone. J Biol Chem 277:28512–28520PubMedCrossRef

Polymeropoulos M, Lavedan C, Leroy E, Ide E, Deheia A, Rutru A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos S, Chandrasekharappa S, Athanassiadou A, Papetropoulous T, Johnson G, Lazzarini M, Duoisin C, Di-Iorio G, Golbe I, Nussbaum R (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science 276:2045–2047PubMedCrossRef

Pountney D, Voelcker N, Gai W (2005) Annular alpha synuclein oligomers are potentially toxic agents in alpha synucleinopathy. Hypothesis. Neurotox Res 7:59–67PubMedCrossRef

Rang HP (2001) Pharmacology, 4th edn. Churchill Livingstone, New York

Reeve HL, Vaughan PF, Peers C (1994) Calcium channel currents in undifferentiated human neuroblastoma (SH-SY5Y) cells: actions and possible interactions of dihydropyridines and omega-conotoxin. Eur J Neurosci 6:943–952PubMedCrossRef

Riascos D et al (2011) Age-related loss of calcium buffering and selective neuronal vulnerability in Alzheimer’s disease. Acta Neuropathol 122:565–576PubMedCrossRef

Søgaard R, Ljungstrøm T, Pedersen KA, Olesen SP, Jensen BS (2001) KCNQ4 channels expressed in mammalian cells: functional characteristics and pharmacology. Am J Physiol Cell Physiol 280:C859–C866PubMed

Sonnier H, Kolomytkin OV, Marino AA (2000) Resting potential of excitable neuroblastoma cells in weak magnetic fields. Cell Mol Life Sci 57:514–520PubMedCrossRef

Talley E, Cribbs LL, Lee J-H, Daud A, Perez-Reyes E, Bayliss DA (1999) Differential distribution of three members of a gene family encoding low voltage-activated (t-type) calcium channels. J Neurosci 19:1895–1911PubMed

Uversky VN, Eliezer D (2009) Biophysics of Parkinson’s disease: structure and aggregation of alpha-synuclein. Curr Protein Pept Sci 10:483–499PubMedCrossRef

Wen X et al (2011) T-type calcium channel expression in cultured human neuroblastoma cells. Neural Regen Res 6(31):2405–2409

Wildburger NC, Lin-Ye A, Baird MA, Lei D, Bao J (2009) Neuroprotective effects of blockers for T-type calcium channels. Mol Neurodegener 4:1–8CrossRef

Wojda U, Salinska E, Kuznicki J (2008) Calcium ions in neuronal degeneration. IUBMB Life 60(9):575–590PubMedCrossRef

Yamada T, McGeer PL, Baimbridge KG, McGeer EG (1990) Relative sparing in Parkinson’s disease of substantia nigra dopamine neurons containing calbindin-D28K. Brain Res 526:303–307PubMedCrossRef

Yunker MA (2003) Modulation and pharmacology of low voltage-activated T-type calcium channels. J Bioenerg Biomembr 35:577–598PubMedCrossRef

Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R, Ampuero I, Vidal L, Hoenicka J, Rodriguez O, Atares B, Llorens V, Gomez Tortosa E, del Ser T, Munoz DG, de Yebenes JG (2004) The new mutation, E46K, of alpha synuclein causes Parkinson’s disease and Lewy Body Dementia. Ann Neurol 55:164–173PubMedCrossRef

Title: Potassium Depolarization and Raised Calcium Induces α-Synuclein Aggregates
Authors: Jordan Follett
Bonnie Darlow
Mathew B. Wong
Jacob Goodwin
Dean L. Pountney
Publication date: 01-05-2013
Publisher: Springer-Verlag
Published in: Neurotoxicity Research / Issue 4/2013
Print ISSN: 1029-8428
Electronic ISSN: 1476-3524
DOI: https://doi.org/10.1007/s12640-012-9366-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Potassium Depolarization and Raised Calcium Induces α-Synuclein Aggregates

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2013

Pressor Response to Oral Tyramine and Monoamine Oxidase Inhibition During Treatment with Ralfinamide (NW-1029)

α-Synuclein Protects Neurons from Apoptosis Downstream of Free-Radical Production Through Modulation of the MAPK Signalling Pathway

Effect of l-Tyrosine In Vitro and In Vivo on Energy Metabolism Parameters in Brain and Liver of Young Rats

Excitotoxicity in the Pathogenesis of Autism

Excitotoxicity Through NMDA Receptors Mediates Cerebellar Granule Neuron Apoptosis Induced by Prion Protein 90-231 Fragment

Regulation of FMO and PON Detoxication Systems in ALS Human Tissues